we provided evidence that PMF patients have a relevant and life-threatening risk of thrombosis and that the lower-risk IPSS categories (low/intermediate-1) harboring the JAK2 V617F mutation are at the highest risk. In clinical practice, this risk could justify studies testing primary prophylaxis with low-dose aspirin in all positive JAK2 V617F patients, particularly in those with lower-risk IPSS scores, if not otherwise contraindicated.
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
Rumi E;Vanni D;Borsani O;
2022-01-01
Abstract
we provided evidence that PMF patients have a relevant and life-threatening risk of thrombosis and that the lower-risk IPSS categories (low/intermediate-1) harboring the JAK2 V617F mutation are at the highest risk. In clinical practice, this risk could justify studies testing primary prophylaxis with low-dose aspirin in all positive JAK2 V617F patients, particularly in those with lower-risk IPSS scores, if not otherwise contraindicated.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.